New scientific statement of the European Society of Hypertension on the management of hypertension Review article

Main Article Content

Piotr Jędrusik

Abstract

The European Society of Hypertension has recently published a scientific statement updating its 2007 guidelines on the management of hypertension. This document summarizes the most important data published within the last two years that warrant some changes and additions in the treatment guidelines, including new data regarding the importance of target organ damage in total cardiovascular risk stratification, new analyses on threshold and target blood pressure values during treatment, the choice of antihypertensive drugs, in particular regarding the use of beta-blockers as first-line therapy, the importance of combined therapy and the use of fixed-dose co mbinations in the treatment of hypertension, and the approach to treatment in special populations, including the very elderly in whom convincing data showing outcome benefits of antihypertensive therapy have been recently published.

Downloads

Download data is not yet available.

Article Details

How to Cite
Jędrusik , P. (2009). New scientific statement of the European Society of Hypertension on the management of hypertension. Cardiology in Practice, 3(4), 154-160. Retrieved from https://journalsmededu.pl/index.php/kwp/article/view/1647
Section
Articles

References

1. Mancia G., Laurent S., Agabiti-Rosei E. et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009, 27: 2121-2158.
2. Guidelines Committee. 2007 Guidelines for the Management of Arterial Hypertension The Task Force for Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens 2007, 25: 1105-1187.
3. Zanchetti A., Grassi G., Mancia G.: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J. Hypertens. 2009, 27: 923-934.
4. Zanchetti A.: Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J. Hypertens. 2009, 27: 1509-1520.
5. Law M.R., Morris J.K., Wald N.J.: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338: 1665-1683.
6. Bangalore S., Sawhney S., Messerli F.H.: Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J. Am. Coll. Cardiol. 2008, 52: 1482-1489.
7. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370: 829-840.
8. Beckett N.S., Peters R., Fletcher A.E. et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med. 2008, 358: 1887-1898.
9. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al.; Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008, 358: 1547-1559.
10. Jamerson K., Weber M.A., Bakris G.L. et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008, 359: 2417-2428.